Scoop: Gilead outlines plans to muscle up its manufacturing arm after Immunomedics layoffs
Gilead has had a no good, very bad week thus far. On Monday, the company revealed Phase III data for its prized $21 billion Immunomedics drug that fell flat on Wall Street, and then Tuesday, reports first emerged that Gilead is planning to lay off 114 staffers from Immunomedics’ former headquarters — a move planned no later than February but whose timing coincidentally proved unfortunate.
Now there’s a new shift to the narrative in the works — which will include some future hiring plans.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters